M. Benjamin Major, PhD

Medical School Department Cell Biology and Physiology
Research Program Mechanisms of Cancer Biology Program
M. Benjamin Major

Researcher Background

Primary Academic Title

Alan A. and Edith L. Wolff Professor Department of Cell Biology & Physiology Department of Otolaryngology, WashU Medicine

Training

  • 2007 - 2009: Postdoctoral, Pharmacology, University of Washington, Seattle, WA

Education

  • 2004: PhD, University of Utah, Salt Lake City, UT

Research & Selected Publications

Research Interest

Understanding how alterations in signal transduction pathways contribute to human cancer, and whether exploitation of that understanding can aid in the development of new diagnostics, prognosis and therapeutic intervention strategies.

Research Publications

A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth.
Authors:

Roy N, Wyseure T, Lo IC, one or more additional authors omitted Major MB, one or more additional authors omitted Patricelli MP

Journal & Year:

Cancer Discov • 2026

Pyrimethamine and a potent analog inhibit NRF2 by suppressing one-carbon metabolism.
Authors:

Chembo J, Bowman BM, Lapak K, one or more additional authors omitted Major MB

Journal & Year:

J Biol Chem • 2025

Stable Cas9 expression regulates cell growth by facilitating mTORC2 activation.
Authors:

Yu L, Jin Y, Chen J, one or more additional authors omitted Major MB, Liu P

Journal & Year:

Nucleic Acids Res • 2025

A SETD2-CDK1-lamin axis maintains nuclear morphology and genome stability.
Authors:

Khan A, Zhang C, Nguyen PG, one or more additional authors omitted Major MB, one or more additional authors omitted Strahl BD

Journal & Year:

Nat Cell Biol • 2025

Association between Locoregional Failure and NFE2L2/KEAP1/CUL3 Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer.
Authors:

Guan L, Torres-Saavedra PA, Zhao X, Major MB, one or more additional authors omitted Hayes DN

Journal & Year:

Clin Cancer Res • 2025

Pyrimethamine and a potent analogue WCDD115 inhibit NRF2 by suppressing DHFR and one-carbon metabolism.
Authors:

Chembo J, Bowman BM, Lapak K, one or more additional authors omitted Major MB

Journal & Year:

bioRxiv • 2025

Engineered Cas9 variants bypass Keap1-mediated degradation in human cells and enhance epigenome editing efficiency.
Authors:

Chen J, Su S, Pickar-Oliver A, one or more additional authors omitted Major MB, one or more additional authors omitted Liu P

Journal & Year:

Nucleic Acids Res • 2024

Mutant Nrf2E79Q enhances the promotion and progression of a subset of oncogenic Ras keratinocytes and skin tumors.
Authors:

Witherspoon JG, Hall JR, Jima D, one or more additional authors omitted Major MB, one or more additional authors omitted Smart RC

Journal & Year:

Redox Biol • 2024